$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

$mtnb Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222030195 Filed on November 02, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$1.063M	$1.063M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.676M	$2.818M	$2.257M
YoY Change	8.16%	24.88%	-4.55%
% of Gross Profit
Research & Development	$3.867M	$3.707M	$4.621M
YoY Change	-8.8%	-19.79%	38.52%
% of Gross Profit
Depreciation & Amortization	$96.73K	$92.61K	$70.86K
YoY Change	35.46%	30.69%	6.62%
% of Gross Profit
Operating Expenses	$6.543M	$3.707M	$6.878M
YoY Change	-2.55%	-46.11%	20.66%
Operating Profit		-$5.463M	-$6.878M
YoY Change		-20.58%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$88.25K	$988.00	$41.39K
YoY Change	505.7%	-97.61%	-73.31%
Pretax Income	-$3.635M	-$5.462M	-$6.837M
YoY Change	-45.75%	-20.11%	25.45%
Income Tax
% Of Pretax Income
Net Earnings	-$3.635M	-$5.462M	-$6.837M
YoY Change	-45.75%	-20.11%	25.45%
Net Earnings / Revenue	-341.91%	-514.03%
Basic Earnings Per Share		-$0.03	-$0.03
Diluted Earnings Per Share	-$0.02	-$25.18K	-$31.77K
COMMON SHARES
Basic Shares Outstanding	216.9M shares	216.9M shares	215.2M shares
Diluted Shares Outstanding		216.9M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.76M	$33.05M	$53.83M
YoY Change	-42.04%	-38.6%	-14.24%
Cash & Equivalents	$6.830M	$11.18M	$24.92M
Short-Term Investments	$21.93M	$21.88M	$28.91M
Other Short-Term Assets	$5.769M	$4.048M	$2.651M
YoY Change	320.64%	52.68%	9.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.53M	$37.10M	$56.48M
YoY Change	-32.28%	-34.32%	-13.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.091M	$2.144M	$5.950M
YoY Change	35.96%	-63.97%	17.83%
Goodwill	$1.336M	$1.336M
YoY Change	-0.04%
Intangibles	$3.017M	$3.017M
YoY Change	-0.01%
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$10.29M	$10.45M	$10.50M
YoY Change	-0.44%	-0.54%	9.38%
TOTAL ASSETS
Total Short-Term Assets	$34.53M	$37.10M	$56.48M
Total Long-Term Assets	$10.29M	$10.45M	$10.50M
Total Assets	$44.82M	$47.55M	$66.98M
YoY Change	-26.92%	-29.02%	-10.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$618.0K	$656.7K	$662.0K
YoY Change	-34.13%	-0.8%	77.45%
Accrued Expenses	$3.099M	$3.697M	$2.181M
YoY Change	8.7%	69.53%	-6.37%
Deferred Revenue	$721.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.000K	$7.860K	$24.31K
YoY Change	-66.73%	-67.67%	-24.69%
Total Short-Term Liabilities	$4.286M	$4.902M	$4.099M
YoY Change	-1.44%	19.58%	44.42%
LONG-TERM LIABILITIES
Long-Term Debt	$22.00K	$0.00	$5.750K
YoY Change	739.69%	-100.0%	-80.87%
Other Long-Term Liabilities	$3.533M	$3.684M	$4.285M
YoY Change	-14.67%	-14.02%	26.33%
Total Long-Term Liabilities	$3.896M	$4.025M	$4.290M
YoY Change	-13.12%	-6.18%	25.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.286M	$4.902M	$4.099M
Total Long-Term Liabilities	$3.896M	$4.025M	$4.290M
Total Liabilities	$8.182M	$8.927M	$8.731M
YoY Change	-7.37%	2.25%	32.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.6M	-$149.0M
YoY Change	15.95%
Common Stock	$22.00K	$21.69K
YoY Change	1.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.64M	$38.62M	$58.25M
YoY Change
Total Liabilities & Shareholders Equity	$44.82M	$47.55M	$66.98M
YoY Change	-26.92%	-29.02%	-10.46%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$3.635M	-$5.462M	-$6.837M
YoY Change	-45.75%	-20.11%	25.45%
Depreciation, Depletion And Amortization	$96.73K	$92.61K	$70.86K
YoY Change	35.46%	30.69%	6.62%
Cash From Operating Activities	-$4.299M	-$4.969M	-$5.750M
YoY Change	8.63%	-13.59%	10.01%
INVESTING ACTIVITIES
Capital Expenditures	$41.60K	-$250.4K	-$224.2K
YoY Change	-214.95%	11.67%
Acquisitions
YoY Change
Other Investing Activities	-$410.00	$6.000M	$466.9K
YoY Change	-100.44%	1185.1%	-116.79%
Cash From Investing Activities	-$42.01K	$5.750M	$242.7K
YoY Change	-174.13%	2269.04%	-108.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.640K	-3.650K	-8.320K
YoY Change	-157.35%	-56.13%	-115.35%
NET CHANGE
Cash From Operating Activities	-4.299M	-4.969M	-5.750M
Cash From Investing Activities	-42.01K	5.750M	242.7K
Cash From Financing Activities	-4.640K	-3.650K	-8.320K
Net Change In Cash	-4.346M	777.3K	-5.516M
YoY Change	11.64%	-114.09%	-30.65%
FREE CASH FLOW
Cash From Operating Activities	-$4.299M	-$4.969M	-$5.750M
Capital Expenditures	$41.60K	-$250.4K	-$224.2K
Free Cash Flow	-$4.341M	-$4.718M	-$5.526M
YoY Change	10.7%	-14.61%	5.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001582554
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	MTNB	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod		shares
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	MTNB	Stock Issued During Period Value Issuance Of Common Stock From Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfWarrants		usd
	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2021Q3	MTNB	Stock Issued During Period Value Issuance Of Common Stock From Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfWarrants		usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff		usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	MTNB	Unearned Restricted Stock Grants UnearnedRestrictedStockGrants		usd
	MTNB	Stock Dividends Issued StockDividendsIssued		usd
	MTNB	Cashless Exercise Of Warrants CashlessExerciseOfWarrants		usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount		usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	MTNB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Tendered ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38022
	dei	Entity Registrant Name EntityRegistrantName	MATINAS BIOPHARMA HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3011414
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1545 Route 206 South
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bedminster
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07921
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	484-8805
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	MTNB
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	216864526	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11175838	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21029806	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	21875015	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	28592049	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3997798	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1321466	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	37098651	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	50993321	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2144102	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1537728	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3742019	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4218890	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	7026	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	22270	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3017377	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3017377	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1336488	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1336488	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	200000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	200000	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	10447012	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	10332753	usd
CY2022Q3	us-gaap	Assets Assets	47545663	usd
CY2021Q4	us-gaap	Assets Assets	61326074	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	656717	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	938270	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3696932	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2850888	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	540076	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	538546	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7860	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	21039	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4901585	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4348743	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	341265	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	341265	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3683949	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4140387	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2621	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4025214	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4484273	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8926799	usd
CY2021Q4	us-gaap	Liabilities Liabilities	8833016	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	216864526	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	216864526	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	216269450	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	216269450	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	21685	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	21627	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	188529404	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	184251138	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148996657	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131634208	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-935568	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-145499	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	38618864	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	52493058	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47545663	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61326074	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1062500	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2125000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33333	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3706828	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4621255	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12811462	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10343451	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2818252	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2256689	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8423868	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7710625	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	6525080	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	6877944	usd
	us-gaap	Costs And Expenses CostsAndExpenses	21235330	usd
	us-gaap	Costs And Expenses CostsAndExpenses	18054076	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5462580	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6877944	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19110330	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18020743	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1734133	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1328470	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	988	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41394	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13748	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	108298	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5461592	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6836550	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17362449	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16583975	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	395799	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5461592	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6836550	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17362449	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16979774	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216864526	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	215179949	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216792083	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	208130431	shares
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-181152	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-52837	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-790069	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-229766	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-181152	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-52837	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-790069	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-229766	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5642744	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6889387	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18152518	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16813741	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	52493058	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3887682	usd
	MTNB	Stock Issued During Period Value Common Stock In Exchange For Options StockIssuedDuringPeriodValueCommonStockInExchangeForOptions	99441	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	291200	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-790069	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17362449	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	38618864	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42848537	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1413070	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-181152	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5461592	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	38618864	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	63730697	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3132351	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23814	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5580471	usd
	MTNB	Stock Issued During Period Value Common Stock In Exchange For Options StockIssuedDuringPeriodValueCommonStockInExchangeForOptions	1400658	usd
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1500000	shares
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1200000	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-229766	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16583975	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	58254250	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	62903750	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1031949	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7938	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1500000	shares
CY2021Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1200000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-52837	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6836550	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	58254250	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17362449	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16583975	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	244024	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	179421	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3887682	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3217497	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	412909	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	367661	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	15244	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	29300	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	157553	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	172227	usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	291200	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1200000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-390945	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-335833	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2676332	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-77333	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-281553	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	312057	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	846044	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	98574	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14856622	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11265738	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9480588	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17787465	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	15250000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	34725000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	850399	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	224188	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4919013	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16713347	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5580471	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	99441	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1400658	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15800	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	24459	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83641	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6956670	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9853968	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12404279	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21279806	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12768481	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11425838	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25172760	usd
	MTNB	Unrealized Loss On Securities For Sale UnrealizedLossOnSecuritiesForSale	-790069	usd
	MTNB	Unrealized Loss On Securities For Sale UnrealizedLossOnSecuritiesForSale	-229766	usd
	us-gaap	Stock Issued1 StockIssued1	3797705	usd
	MTNB	Unearned Restricted Stock Grants UnearnedRestrictedStockGrants	7189	usd
	MTNB	Stock Dividends Issued StockDividendsIssued	843600	usd
	MTNB	Right Of Use Asset In Exchange From Liabilities From Operating Lease RightOfUseAssetInExchangeFromLiabilitiesFromOperatingLease	-63964	usd
	MTNB	Right Of Use Asset In Exchange From Liabilities From Operating Lease RightOfUseAssetInExchangeFromLiabilitiesFromOperatingLease	1443610	usd
	MTNB	Cashless Exercise Of Warrants CashlessExerciseOfWarrants	12	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_ziBWU8DYUc7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_827_zXW3YZH4f8u5">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28592	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	8257000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	20335000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	28592000	usd
CY2022Q3	us-gaap	Cash Cash	11200000	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	21900000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	300000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	250000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	250000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11176000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21030000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24923000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12432000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	250000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	250000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	250000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	336000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11426000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21280000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25173000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12768000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	181000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	790000	usd
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	53000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	230000	usd
CY2022Q3	MTNB	Marketable Securities Accumulated Unrealized Gain MarketableSecuritiesAccumulatedUnrealizedGain	936000	usd
CY2021Q4	MTNB	Marketable Securities Accumulated Unrealized Gain MarketableSecuritiesAccumulatedUnrealizedGain	145000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22811	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	936	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21875	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	10349000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	11526000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	21875000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28737	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	147	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	147	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	21875000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	28592000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3425000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2575000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1281000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1037000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2144000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1538000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	89000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	244000	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	62000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	179000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1462000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1343000	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1408000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	33000	usd
CY2022Q3	MTNB	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	334000	usd
CY2021Q4	MTNB	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	381000	usd
CY2022Q3	MTNB	Accrued General And Administrative Expenses Current AccruedGeneralAndAdministrativeExpensesCurrent	299000	usd
CY2021Q4	MTNB	Accrued General And Administrative Expenses Current AccruedGeneralAndAdministrativeExpensesCurrent	195000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	194000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	899000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3697000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2851000	usd
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.
CY2022Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P12M
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	194000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	646000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	626000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	138000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	413000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	125000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	368000	usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	15000	usd
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	9000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	29000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	225000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	6000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	916000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	956000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	998000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1040000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1355000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1112000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5490000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	8000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1266000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4224000	usd
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	8000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.092	pure
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.070	pure
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	883000	usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	22000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	922000	usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	962000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1004000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1046000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1112000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5929000	usd
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	24000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1250000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4679000	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	24000	usd
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.078	pure
	MTNB	Sale Of Net Operating Losses SaleOfNetOperatingLosses	1700000	usd
	MTNB	Sale Of Net Operating Losses SaleOfNetOperatingLosses	1300000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	988000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1328000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	320000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	20000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	988000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	988000	shares
CY2022Q3	MTNB	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice	0.56
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28770000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23230000	shares
CY2021Q4	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-145000	usd
CY2021Q4	us-gaap	Aoci Tax Attributable To Parent AociTaxAttributableToParent	-145000	usd
	MTNB	Net Unrealized Gains Losses On Availableforsale Securities Net Unrealized Loss On Securities Availableforsale NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale	-791000	usd
	MTNB	Accumulated Other Comprehensive Lossgain Net Unrealized Loss On Securities Availableforsale AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale	-791000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-791000	usd
	MTNB	Accumulated Other Comprehensive Income Loss Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax	-791000	usd
CY2022Q3	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-936000	usd
CY2022Q3	us-gaap	Aoci Tax Attributable To Parent AociTaxAttributableToParent	-936000	usd
CY2020Q4	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	228000	usd
CY2020Q4	us-gaap	Aoci Tax Attributable To Parent AociTaxAttributableToParent	228000	usd
	MTNB	Net Unrealized Gains Losses On Availableforsale Securities Net Unrealized Loss On Securities Availableforsale NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale	-230000	usd
	MTNB	Accumulated Other Comprehensive Lossgain Net Unrealized Loss On Securities Availableforsale AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale	-230000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-230000	usd
	MTNB	Accumulated Other Comprehensive Income Loss Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax	-230000	usd
CY2021Q3	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-2000	usd
CY2021Q3	us-gaap	Aoci Tax Attributable To Parent AociTaxAttributableToParent	-2000	usd
CY2022Q1	MTNB	Increased Shares Of Common Stock Outstanding IncreasedSharesOfCommonStockOutstanding	8651000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1413000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1061000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3888000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3217000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	28184000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1095000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	195000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	165000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1137000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27782000	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	0	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	8000	shares
CY2021Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	29000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	85000	usd
	MTNB	Commercial Fees CommercialFees	7700000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-22-030195-index-headers.html	Edgar Link	pending
0001493152-22-030195-index.html	Edgar Link	pending
0001493152-22-030195.txt	Edgar Link	pending
0001493152-22-030195-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mtnb-20220930.xsd	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
mtnb-20220930_pre.xml	Edgar Link	unprocessable
mtnb-20220930_def.xml	Edgar Link	unprocessable
mtnb-20220930_lab.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mtnb-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

2022 Q4 Form 10-Q Financial Statement

#000149315222030195 Filed on November 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB Matinas BioPharma Holdings, Inc. Stock $mtnb

2022 Q4 Form 10-Q Financial Statement

#000149315222030195 Filed on November 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb